Follow
Chris Harbron
Chris Harbron
Unknown affiliation
Verified email at roche.com
Title
Cited by
Cited by
Year
Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis
A Kindmark, A Jawaid, CG Harbron, BJ Barratt, OF Bengtsson, ...
The pharmacogenomics journal 8 (3), 186-195, 2008
4012008
Evaluating robustness and sensitivity of the NanoString technologies nCounter platform to enable multiplexed gene expression analysis of clinical samples
MH Veldman-Jones, R Brant, C Rooney, C Geh, H Emery, CG Harbron, ...
Cancer research 75 (13), 2587-2593, 2015
3452015
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)
JR Dry, S Pavey, CA Pratilas, C Harbron, S Runswick, D Hodgson, ...
Cancer research 70 (6), 2264-2273, 2010
2642010
Covert manipulation of the ratio of medium-to long-chain triglycerides in isoenergetically dense diets: effect on food intake in ad libitum feeding men.
RJ Stubbs, CG Harbron
International journal of obesity and related metabolic disorders: journal of …, 1996
1421996
Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease
J Armstrong, C Harbron, S Lea, G Booth, P Cadden, KA Wreggett, ...
Journal of Pharmacology and Experimental Therapeutics 338 (3), 732-740, 2011
972011
Reproducible, quantitative, and flexible molecular subtyping of clinical DLBCL samples using the NanoString nCounter system
MH Veldman-Jones, Z Lai, M Wappett, CG Harbron, JC Barrett, ...
Clinical cancer research 21 (10), 2367-2378, 2015
782015
Personalized medicine and proteomics: lessons from non-small cell lung cancer
G Marko-Varga, A Ogiwara, T Nishimura, T Kawamura, K Fujii, ...
Journal of proteome research 6 (8), 2925-2935, 2007
692007
Embracing model-based designs for dose-finding trials
SB Love, S Brown, CJ Weir, C Harbron, C Yap, B Gaschler-Markefski, ...
British journal of cancer 117 (3), 332-339, 2017
672017
In search of preclinical robustness
IS Peers, PR Ceuppens, C Harbron
Nature reviews Drug discovery 11 (10), 733-734, 2012
642012
Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 …
C Pott, E Hoster, B Kehden, M Unterhalt, M Herold, RH van der Jagt, ...
Blood 128 (22), 613, 2016
562016
RefPlus: an R package extending the RMA Algorithm
C Harbron, KM Chang, MC South
Bioinformatics 23 (18), 2493-2494, 2007
522007
Synthetic data use: exploring use cases to optimise data utility
S James, C Harbron, J Branson, M Sundler
Discover Artificial Intelligence 1 (1), 15, 2021
462021
A statistician's perspective on biomarkers in drug development
M Jenkins, A Flynn, T Smart, C Harbron, T Sabin, J Ratnayake, P Delmar, ...
Pharmaceutical statistics 10 (6), 494-507, 2011
462011
The use of external controls: To what extent can it currently be recommended?
HU Burger, C Gerlinger, C Harbron, A Koch, M Posch, J Rochon, A Schiel
Pharmaceutical Statistics 20 (6), 1002-1016, 2021
412021
P38 MAPK and glucocorticoid receptor crosstalk in bronchial epithelial cells
S Lea, J Li, J Plumb, K Gaffey, S Mason, R Gaskell, C Harbron, D Singh
Journal of Molecular Medicine 98, 361-374, 2020
352020
A flexible unified approach to the analysis of pre‐clinical combination studies
C Harbron
Statistics in medicine 29 (16), 1746-1756, 2010
352010
Corticosteroid insensitive alveolar macrophages from asthma patients; synergistic interaction with a p38 mitogen‐activated protein kinase (MAPK) inhibitor
S Lea, C Harbron, N Khan, G Booth, J Armstrong, D Singh
British journal of clinical pharmacology 79 (5), 756-766, 2015
312015
Analysis of minimal residual disease in follicular lymphoma patients in GADOLIN, a phase III study of obinutuzumab plus bendamustine versus bendamustine in relapsed/refractory …
C Pott, D Belada, N Danesi, G Fingerle-Rowson, J Gribben, C Harbron, ...
Blood 126 (23), 3978, 2015
292015
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial
C Pott, LH Sehn, D Belada, J Gribben, E Hoster, B Kahl, B Kehden, ...
Leukemia 34 (2), 522-532, 2020
272020
Proteomic biomarkers for acute interstitial lung disease in gefitinib-treated Japanese lung cancer patients
F Nyberg, A Ogiwara, CG Harbron, T Kawakami, K Nagasaka, S Takami, ...
Plos one 6 (7), e22062, 2011
242011
The system can't perform the operation now. Try again later.
Articles 1–20